Does pioglitazone improve cardiac function and alter myocardial substrate metabolism in patients with well-controlled type 2 diabetes mellitus?
In patients with well-controlled T2DM, pioglitazone improves left ventricular diastolic function and insulin sensitivity without affecting cardiac triglyceride accumulation or high-energy phosphate metabolism.
In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity. The functional changes, however, were not associated with myocardial substrate and high-energy phosphate metabolism.
Meer et al. (Tue,) studied this question.